*代表通讯作者,# 代表共同第一作者
1. Jing LK, Qian ZH, Gao Q, Sun R, Zhen ZL, Wang GH, Yang XY, Li HT, Guo TN, Zhang W*. Diffuse Midline Glioma Treated with Epigenetic Agent Based Immunotherapy. Signal Transduct Target Ther. 2023;8(1):23.
2. Chen WJ, Zhang X, Han H, Lv JN, Kang EM, Zhang YL, Liu WP, He XS, Wang J, Wang GH, Yu YB, Zhang W*. The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status. Cell Death Dis. 2020; 11(8): 668-681.
3. Zhang X, Zhang W#, Mao XG, Cao WD, Zhen HN, Hu SJ. Malignant Intracranial High Grade Glioma and Current Treatment Strategy. Curr Cancer Drug Targets. 2019; 19(2): 101-108.
4. Zhang W, Fulci G, Wakimoto H, Cheema AT, Buhrman JS, Jeyaretna DS, Stemmer-Rachamimov AO, Rabkin SD, Martuza RL. Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models. Neoplasia. 2013; 15(6):591-9.
5. Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL. Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bevacizumab-induced Invasion in U87 Glioma. Mol Ther. 2012; 20(1):37-45.
6. Zhang W, Kawanishi M, Miyake K, Kagawa M, Kawai N, Murao K, Nishiyama A, Fei Z, Zhang X, Tamiya T. Association between YKL-40 and adult primary astrocytoma. Cancer. 2010; 116(11):2688-97.
7. Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, Miyake K, Kawai N, Fei Z, Tamiya T. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer. 2010; 10:593.
8. Liu BL, Cheng JX, Zhang W#, Zhang X, Wang R, Lin H, Huo JL, Cheng H. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol. 2010; 12(6):540-8.
9. 章薇, 章翔. 急性成人无骨折与脱位型脊髓损伤的外科救治策略. 中华神经外科疾病研究杂志, 2018, 17(1): 1-3.
10. 章薇, 李兵, 毛星刚, 李剑, 胡世颉, 章翔. 科研与临床相互融合的教学理念与实践. 中华神经外科疾病研究杂志, 2015, 14(2): 164-166.